يعرض 1 - 20 نتائج من 61 نتيجة بحث عن '"Webster, A.C."', وقت الاستعلام: 1.98s تنقيح النتائج
  1. 1
    Academic Journal

    وصف الملف: text

    Relation: https://eprints.gla.ac.uk/319634/2/319634.pdf; Shemilt, R. et al. (2024) Sex differences in cancer outcomes across the range of eGFR. Nephrology Dialysis Transplantation , (doi:10.1093/ndt/gfae059 ) (PMID:38460949) (Early Online Publication)

  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
  5. 5
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Electronic Resource
  9. 9
    Academic Journal
  10. 10
  11. 11
    Academic Journal
  12. 12
  13. 13
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
  17. 17
  18. 18
  19. 19
    Electronic Resource

    مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
    Cochrane Database of Systematic Reviews
    Click here for full text options
    LibKey Link

  20. 20